Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Condition(s):Soft Tissue SarcomaLast Updated:September 7, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Soft Tissue SarcomaLast Updated:September 7, 2022Recruiting
Condition(s):NeuroblastomaLast Updated:September 21, 2023Recruiting
Condition(s):Gastric CancerLast Updated:July 22, 2022Completed
Condition(s):Differentiated Thyroid CarcinomaLast Updated:May 30, 2017Unknown status
Condition(s):Colorectal NeoplasmsLast Updated:June 29, 2023Suspended
Condition(s):Small Cell Lung CancerLast Updated:September 7, 2017Unknown status
Condition(s):Immune Checkpoint InhibitionLast Updated:September 21, 2020Unknown status
Condition(s):Solid TumorLast Updated:May 19, 2022Recruiting
Condition(s):Biliary Tract Cancer; Cholangiocarcinoma; Biomarker; Hepatobiliary NeoplasmLast Updated:June 3, 2021Completed
Condition(s):Soft Tissue Sarcoma, Adult, Stage IILast Updated:May 22, 2017Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.